Shephard Mpofu
- Immunology top 0.5%
- Rheumatology top 0.1%
- Hematology top 0.5%
- Dermatology top 0.5%
- Molecular Biology
- Co-authors
- Hanno B. RichardsPhilip J. MeaseLuminita PricopIain B. McInnesProton RahmanDésirée van der HeijdeBruce KirkhamRuvie Martin
- Topics
- Spondyloarthritis Studies and Treatments (46 papers)Autoimmune and Inflammatory Disorders Research (42 papers)Psoriasis: Treatment and Pathogenesis (39 papers)
- Cited by
- RheumatologyHematologyImmunology
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Shephard Mpofu
68 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Immunology 2.9k
- Rheumatology 2.9k
- Hematology 1.8k
- Dermatology 520
- Molecular Biology 252
Countries citing papers authored by Shephard Mpofu
This map shows the geographic impact of Shephard Mpofu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shephard Mpofu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shephard Mpofu more than expected).
Fields of papers citing papers by Shephard Mpofu
This network shows the impact of papers produced by Shephard Mpofu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shephard Mpofu. The network helps show where Shephard Mpofu may publish in the future.
Co-authorship network of co-authors of Shephard Mpofu
This figure shows the co-authorship network connecting the top 25 collaborators of Shephard Mpofu. A scholar is included among the top collaborators of Shephard Mpofu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shephard Mpofu. Shephard Mpofu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 2 | |
| 3 | 2 | |
| 4 | 26 | |
| 5 | 45 | |
| 6 | 37 | |
| 7 | 128 | |
| 8 | 3 | |
| 9 | Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis | 2 |
| 10 | 61 | |
| 11 | Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study | 2 |
| 12 | Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial | 4 |
| 13 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study | 12 |
| 14 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing | 19 |
| 15 | Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | 16 |
| 16 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial | 12 |
| 17 | 83 | |
| 18 | 19 | |
| 19 | 1 | |
| 20 | 227 |
About Shephard Mpofu
Shephard Mpofu is a scholar working on Rheumatology, Hematology and Immunology, having authored 68 papers that have together received 4.1k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (46 papers), Autoimmune and Inflammatory Disorders Research (42 papers) and Psoriasis: Treatment and Pathogenesis (39 papers). The work is most often cited by research in Rheumatology (2.9k citations), Hematology (1.8k citations) and Immunology (2.9k citations). Shephard Mpofu has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Hanno B. Richards, Philip J. Mease, Luminita Pricop, Iain B. McInnes, Proton Rahman, Désirée van der Heijde, Bruce Kirkham, Ruvie Martin, R. Landewé and Xenofon Baraliakos. Their work appears in journals such as New England Journal of Medicine, The Lancet and Annals of the Rheumatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.